Published in Managed Care Business Week, February 14th, 2006
In an "in vitro study," scientists in the United States "sought to determine what compliance minimizes thoracic artificial lung impedance and pump power output."
"A pulsatile pump drove 3.0 cP glycerol through a circuit consisting of an MC3 Biolung preceded by a piston-cylinder (PC, n=5) chamber with a variable compliance or a polyurethane (n=4) chamber with a fixed, yet pressure-dependent, compliance," explained J.W. McGillicuddy and coauthors at the University of Michigan. "Each chamber was tested at flow rates of 1.8, 3.0, and 5.0 L/min and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week